Decreased serum apolipoprotein A1 level predicts poor prognosis of patients with de novo myelodysplastic syndromes
Sign Up to like & getrecommendations! Published in 2022 at "BMC Cancer"
DOI: 10.1186/s12885-022-09248-2
Abstract: Background Myelodysplastic syndromes (MDS) is a group of heterogeneous myeloid clonal diseases originating from hematopoietic stem cells. It has been demonstrated that apolipoproteins A1(ApoA1) are associated with disease risk in many cancer types. However, there… read more here.
Keywords: mds patients; level; low apoa1; myelodysplastic syndromes ... See more keywords